{"id":"NCT00996125","sponsor":"GlaxoSmithKline","briefTitle":"Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects","officialTitle":"Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) 580299 Vaccine in Healthy Chinese Female Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-24","primaryCompletion":"2010-12-08","completion":"2010-12-08","firstPosted":"2009-10-16","resultsPosted":"2012-06-27","lastUpdate":"2018-08-17"},"enrollment":750,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Infections, Papillomavirus"],"interventions":[{"type":"BIOLOGICAL","name":"CervarixTM","otherNames":[]},{"type":"OTHER","name":"Control","otherNames":[]}],"arms":[{"label":"Cervarix Group","type":"EXPERIMENTAL"},{"label":"Placebo Group","type":"EXPERIMENTAL"}],"summary":"This study is designed to evaluate the immunogenicity and safety of GlaxoSmithKline Biologicals' human papillomavirus (HPV) vaccine in pre-teen and adolescent female subjects aged 9 - 17 years. One group of subjects will receive the HPV vaccine and the other group will receive the control.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) for Antibodies Against Human Papillomavirus (HPV)-16/18 Antigens","timeFrame":"One month after the third dose (at Month 7)","effectByArm":[{"arm":"Cervarix Group","deltaMin":18347.1,"sd":null},{"arm":"Placebo Group","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":14},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["25424785"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":374},"commonTop":["Pain","Fatigue","Headache","Myalgia","Upper respiratory tract infection"]}}